December 20, 2019
Astellas Pharma and Seattle Genetics said on December 18 that they have won the US FDA’s accelerated approval for their antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) for the treatment of certain adult patients with advanced urothelial cancer. The quick green...read more